blinkx

  • Preventing Blood Clots

  • 00:02:47
  • Sclipo
    • Browse

Preventing Blood Clots

Visit http://bayer.vtenews.ca for more information. Toronto, Ontario - September 16, 2008 – Today, Canada became the first country to approve Xarelto® (rivaroxaban), the first in a new class of anticoagulants, for the prevention of venous thromboembolic events (VTE), or blood clots, in patients who have undergone elective total hip or total knee replacement surgery. As a direct factor Xa inhibitor, Xarelto targets an enzyme that acts as a ‘switch’ to control clotting, reducing the risk of potentially deadly blood clots that can form post hip or knee replacement surgery.

Sclipo | September 16, 2008Watch more videos from Sclipo

Tags:. .undergone. .clotting. .clots. .enzyme. .hip











Acts   Approve   Became   Blood   Canada   Class   Clots   Clotting   Control   Deadly   Elective   Enzyme   Events   Factor   Form   Hip   Knee   Patients   Post   Potentially   Preventing   Prevention   Reducing   Replacement   Risk   September   Surgery   Targets   Toronto Ontario   Total   Undergone